tiprankstipranks
Lenz Therapeutics, Inc. (LENZ)
NASDAQ:LENZ
US Market
LENZ
LENZ Therapeutics
RESEARCH TOOLSreports
Want to see LENZ full AI Analyst Report?

LENZ Therapeutics (LENZ) Stock Forecast & Price Target

412 Followers
See the Price Targets and Ratings of:

LENZ Analyst Ratings

Strong Buy
6Ratings
Strong Buy
5 Buy
1 Hold
0 Sell
Based on 6 analysts giving stock ratings to
LENZ
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

LENZ Stock 12 Month Forecast

Average Price Target

$32.20
▲(487.59% Upside)
Based on 6 Wall Street analysts offering 12 month price targets for LENZ Therapeutics in the last 3 months. The average price target is $32.20 with a high forecast of $60.00 and a low forecast of $12.00. The average price target represents a 487.59% change from the last price of $5.48.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","61":"$61","18.25":"$18.25","32.5":"$32.5","46.75":"$46.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":60,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$60.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":32.2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$32.20</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$12.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,18.25,32.5,46.75,61],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.3,9.507692307692308,13.715384615384615,17.923076923076923,22.130769230769232,26.33846153846154,30.546153846153846,34.753846153846155,38.96153846153846,43.169230769230765,47.37692307692308,51.58461538461538,55.79230769230769,{"y":60,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.3,7.36923076923077,9.438461538461539,11.50769230769231,13.576923076923077,15.646153846153847,17.715384615384618,19.784615384615385,21.853846153846156,23.923076923076927,25.992307692307694,28.061538461538465,30.130769230769236,{"y":32.2,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.3,5.815384615384615,6.3307692307692305,6.846153846153847,7.361538461538462,7.876923076923077,8.392307692307693,8.907692307692308,9.423076923076923,9.938461538461539,10.453846153846154,10.96923076923077,11.484615384615385,{"y":12,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":29.96,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.25,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.05,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.72,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.4,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.3,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.68,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.35,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.88,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.44,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.79,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.3,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$60.00Average Price Target$32.20Lowest Price Target$12.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Piper Sandler Analyst forecast on LENZ
Biren Amin
Piper Sandler
Piper Sandler
$12
Hold
118.98%
Upside
Reiterated
07/09/26
Analysts Are Neutral on These Healthcare Stocks: LENZ Therapeutics (LENZ), Agilent (A)
H.C. Wainwright Analyst forecast on LENZ
Matthew Caufield
H.C. Wainwright
H.C. Wainwright
$38
Buy
593.43%
Upside
Reiterated
07/07/26
Analysts Offer Insights on Healthcare Companies: LENZ Therapeutics (NASDAQ: LENZ), Novavax (NASDAQ: NVAX) and Beam Therapeutics (NASDAQ: BEAM)
William Blair Analyst forecast on LENZ
Lachlan Hanbury Brown
William Blair
William Blair
―
Buy
―
Reiterated
07/06/26
Analysts Offer Insights on Healthcare Companies: Parabilis Medicines, Inc. (NASDAQ: PBLS) and LENZ Therapeutics (NASDAQ: LENZ)
Citi Analyst forecast on LENZ
Yigal Nochomovitz
Citi
Citi
$26→$20
Buy
264.96%
Upside
Assigned
05/13/26
Lenz Therapeutics price target lowered to $20 from $26 at CitiLenz Therapeutics price target lowered to $20 from $26 at Citi
Bank of America Securities Analyst forecast on LENZ
Jason Gerberry
Bank of America Securities
Bank of America Securities
$29→$31
Buy
465.69%
Upside
Reiterated
05/12/26
Lenz Therapeutics price target raised to $31 from $29 at BofALenz Therapeutics price target raised to $31 from $29 at BofA
TD Cowen Analyst forecast on LENZ
Stacy Ku
TD Cowen
TD Cowen
$60
Buy
994.89%
Upside
Reiterated
05/11/26
Analysts Offer Insights on Healthcare Companies: Tectonic Therapeutic (NASDAQ: TECX) and LENZ Therapeutics (NASDAQ: LENZ)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Piper Sandler Analyst forecast on LENZ
Biren Amin
Piper Sandler
Piper Sandler
$12
Hold
118.98%
Upside
Reiterated
07/09/26
Analysts Are Neutral on These Healthcare Stocks: LENZ Therapeutics (LENZ), Agilent (A)
H.C. Wainwright Analyst forecast on LENZ
Matthew Caufield
H.C. Wainwright
H.C. Wainwright
$38
Buy
593.43%
Upside
Reiterated
07/07/26
Analysts Offer Insights on Healthcare Companies: LENZ Therapeutics (NASDAQ: LENZ), Novavax (NASDAQ: NVAX) and Beam Therapeutics (NASDAQ: BEAM)
William Blair Analyst forecast on LENZ
Lachlan Hanbury Brown
William Blair
William Blair
―
Buy
―
Reiterated
07/06/26
Analysts Offer Insights on Healthcare Companies: Parabilis Medicines, Inc. (NASDAQ: PBLS) and LENZ Therapeutics (NASDAQ: LENZ)
Citi Analyst forecast on LENZ
Yigal Nochomovitz
Citi
Citi
$26→$20
Buy
264.96%
Upside
Assigned
05/13/26
Lenz Therapeutics price target lowered to $20 from $26 at CitiLenz Therapeutics price target lowered to $20 from $26 at Citi
Bank of America Securities Analyst forecast on LENZ
Jason Gerberry
Bank of America Securities
Bank of America Securities
$29→$31
Buy
465.69%
Upside
Reiterated
05/12/26
Lenz Therapeutics price target raised to $31 from $29 at BofALenz Therapeutics price target raised to $31 from $29 at BofA
TD Cowen Analyst forecast on LENZ
Stacy Ku
TD Cowen
TD Cowen
$60
Buy
994.89%
Upside
Reiterated
05/11/26
Analysts Offer Insights on Healthcare Companies: Tectonic Therapeutic (NASDAQ: TECX) and LENZ Therapeutics (NASDAQ: LENZ)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
ZURAZura Bio
TNYATenaya Therapeutics
JBIOJade Biosciences
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering LENZ Therapeutics

3 Months
Lachlan Hanbury BrownWilliam Blair
Success Rate
5/14 ratings generated profit
36%
Average Return
-10.19%
Copying Lachlan Hanbury Brown's trades and holding each position for 3 Months would result in 35.71% of your transactions generating a profit, with an average return of -10.19% per trade.
1 Year
Yigal NochomovitzCiti
Success Rate
1/13 ratings generated profit
8%
Average Return
-50.75%
Copying Yigal Nochomovitz's trades and holding each position for 1 Year would result in 7.69% of your transactions generating a profit, with an average return of -50.75% per trade.
2 Years
Lachlan Hanbury BrownWilliam Blair
Success Rate
0/14 ratings generated profit
0%
Average Return
-62.86%
Copying Lachlan Hanbury Brown's trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -62.86% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

LENZ Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
9
11
7
5
1
Buy
3
4
3
3
2
Hold
0
1
1
2
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
12
16
11
10
4
In the current month, LENZ has received 3 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. LENZ average Analyst price target in the past 3 months is 32.20.
Each month's total comprises the sum of three months' worth of ratings.

LENZ Financial Forecast

LENZ Earnings Forecast

Next quarter’s earnings estimate for LENZ is -$1.05 with a range of -$1.37 to -$0.53. The previous quarter’s EPS was -$1.32. LENZ beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 58.33% of the time in the same period. In the last calendar year LENZ has Performed in-line its overall industry.
Next quarter’s earnings estimate for LENZ is -$1.05 with a range of -$1.37 to -$0.53. The previous quarter’s EPS was -$1.32. LENZ beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 58.33% of the time in the same period. In the last calendar year LENZ has Performed in-line its overall industry.

LENZ Sales Forecast

Next quarter’s sales forecast for LENZ is $2.38M with a range of $1.60M to $3.30M. The previous quarter’s sales results were $1.90M. LENZ beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 66.67% of the time in the same period. In the last calendar year LENZ has Performed in-line its overall industry.
Next quarter’s sales forecast for LENZ is $2.38M with a range of $1.60M to $3.30M. The previous quarter’s sales results were $1.90M. LENZ beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 66.67% of the time in the same period. In the last calendar year LENZ has Performed in-line its overall industry.

LENZ Stock Forecast FAQ

What is LENZ’s average 12-month price target, according to analysts?
Based on analyst ratings, Lenz Therapeutics, Inc.’s 12-month average price target is 32.20.
    What is LENZ’s upside potential, based on the analysts’ average price target?
    Lenz Therapeutics, Inc. has 487.59% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is LENZ a Buy, Sell or Hold?
          Lenz Therapeutics, Inc. has a consensus rating of Strong Buy which is based on 5 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Lenz Therapeutics, Inc.’s price target?
            The average price target for Lenz Therapeutics, Inc. is 32.20. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $60.00 ,the lowest forecast is $12.00. The average price target represents 487.59% Increase from the current price of $5.48.
              What do analysts say about Lenz Therapeutics, Inc.?
              Lenz Therapeutics, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 6 Wall Streets Analysts.
                How can I buy shares of LENZ?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.